Die ICPO Foundation förderte durch einen Grant den globalen „Radiopharmaceutical Trial Finder“, entwickelt von WARMTH und Ancora.ai
October 16, 2024 07:00 ET
|
ICPO Foundation
Dieses bahnbrechende, KI-gestützte Tool zur globalen Studienfindung wird auf dem EANM-Kongress 2024 in Hamburg vom 20. bis 22. Oktober 2024 vorgestellt. 16. Oktober 2024 – Wiesbaden, Deutschland und...
ICPO Foundation funded global “Radiopharmaceutical Trial Finder” developed by WARMTH and Ancora.ai
October 16, 2024 07:00 ET
|
ICPO Foundation
This pioneering global trial finder tool powered by AI will be presented at the EANM Congress 2024 in Hamburg from Oct 20-22, 2024 October 16, 2024 – Wiesbaden, Germany and Zurich, Switzerland....
ICPO Foundation geht eine Partnerschaft mit der International Atomic Energy Agency (IAEA) ein
October 10, 2024 04:15 ET
|
ICPO Foundation
Die Parteien kooperieren weltweit im Bereich der therapeutischen klinischen Anwendungen der Nuklearmedizin in der Onkologie. 10. Oktober 2024 – Wiesbaden, Deutschland. Heute kündigte die...
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
October 10, 2024 04:15 ET
|
ICPO Foundation
The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for...
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
September 24, 2024 08:45 ET
|
Curium
Curium opens new Netherlands facility for Lu-177 production, ensuring a steady supply of this breakthrough cancer therapy isotope for over 100,000 patients
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030
September 09, 2024 04:56 ET
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177), Route of Administration (Intravenous, Oral), End User,...
Claritas NucMed Technologies Secures Approval for its Subsidiary Claritas NucMed Tech Brazil to Forge Ahead the Commercialization of its Cutting-Edge Nuclear Medicine Software Solutions in Brazil
September 02, 2024 10:00 ET
|
Claritas HealthTech Ltd
Claritas NucMed Technologies Secures Approval for its Subsidiary Claritas NucMed Tech Brazil to Forge Ahead the Commercialization of its leading SaMDs
North America $3.62 Bn Nuclear Medicine Market by Country, Competition, Forecast & Opportunities, 2019-2023 & 2024-2029
August 26, 2024 10:52 ET
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "North America Nuclear Medicine Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine Global Markets Research 2021-2029: Increasing Demand in Developing Regions, Applications Beyond Oncology, Theranostics Gaining Traction
August 21, 2024 06:57 ET
|
Research and Markets
Dublin, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The "Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market...
Claritas HealthTech Announces Spin-Off of Claritas NucMed Technologies Ltd to Lead Global Delivery of its Suite of Software Solutions in Nuclear Medicine
July 29, 2024 07:30 ET
|
Claritas HealthTech Ltd
Claritas HealthTech Announces Spin-Off of Claritas NucMed Technologies Ltd to Lead Global Delivery of its Suite of Software Solutions in Nuclear Medicine